Search

Displaying results 1301 - 1310 of 8573 in total
  1. Drug

    Bufexamac

    go.drugbank.com/drugs/DB13346
    ApprovedWithdrawn

    Bufexamac was also withdrawn by the EMA in April 2010. … It is typically administered topically for the treatment of subacute and chronic eczema of the skin, including atopic eczema and other inflammatory dermatoses, as well as sunburn and other minor burns,

  2. Drug

    Tryptophan

    go.drugbank.com/drugs/DB00150
    ApprovedInvestigationalNutraceuticalWithdrawn

    It is a precursor of serotonin (hence its use as an antidepressant and sleep aid). It can be a precursor to niacin, albeit inefficiently, in mammals.

    Mixtures: TRAVASOL® SOLUCION BAL 8.5% SIN ELECTROLITOS, EAS ORAL 100 TABLET
  3. Drug

    Bupivacaine

    go.drugbank.com/drugs/DB00297
    ApprovedInvestigational

    Bupivacaine is a widely used local anesthetic agent.

    Mixtures: P-Care 100MX
  4. Drug

    Triflusal

    go.drugbank.com/drugs/DB08814
    ApprovedWithdrawn

    [A31675] It is very important as a secondary prevention of ischemic stroke by offering a lower risk of bleeding.[A31676] It was developed by J.

    Products: GRENDIS 300MG CAPSULE
  5. Drug

    Dostarlimab

    go.drugbank.com/drugs/DB15627
    ApprovedInvestigational

    [L33340] This indication was granted full FDA approval on February 10, 2023.[L45161] Dostarlimab-gxly was granted second accelerated approval for the treatment of solid tumours in the same month. … In April 2021, dostarlimab was granted accelerated approval by the FDA - as GlaxoSmithKline's dostarlimab-gxly (Jemperli) - for the treatment of adult patients with recurrent or advanced mismatch repair

  6. Drug

    Patent Blue

    go.drugbank.com/drugs/DB13967
    ApprovedInvestigational

    [A32574] It has the chemical designation of (4-(alpha-(p-(diethylamino)phenyl)-2,4-disulfobenzylidene)-2,5-cyclohexadiene-1-ylidene)diethylammonium hydroxide. … Patent blue was developed by Guerbet and approved by Health Canada on December 31, 1979.[L1113] The isomer isosulphan is used in the United States for the same indications than patent blue.[A32574]

  7. Indication

    Inborn Errors of Bile Acid Synthesis

    go.drugbank.com/conditions/DBCOND0046673
    Drugs: Cholic Acid
    Synonyms: BASD - Bile acid synthetic defect
  8. Indication

    Memory Disturbances

    go.drugbank.com/conditions/DBCOND0054216
    Drugs: Aniracetam
    Synonyms: Bad memory
  9. Drug

    Ublituximab

    go.drugbank.com/drugs/DB11850
    ApprovedInvestigational

    [A244210, A244215,A241045] Ublituximab was initially developed by LFB Group but was licensed to TG Therapeutics in 2012. … [L44508] The next year, June 2023, ublituximab was also approved by the EMA for the treatment of relapsing forms of multiple sclerosis in adult patients.[L47486]

  10. Drug

    Equine Botulinum Neurotoxin E Immune FAB2

    go.drugbank.com/drugs/DB13897
    Approved

    Equine Botulinum Neurotoxin E Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype E. It is intravenously administered for the treat...

    Mixtures: Bat